Biochemistry, Genetics and Molecular Biology
Proteomics
100%
Mass Spectrometry
43%
Immunoassay
43%
Proteogenomics
42%
Prostate-Specific Antigen
41%
Glycoprotein
25%
Proteome
22%
Glycoproteomics
16%
Tumor Marker
16%
Thrombomodulin
16%
Biomarker Discovery
15%
Glycosylation
14%
Lectin
14%
Cancer Cell
9%
Liquid
9%
Clinical Trial
9%
Enzyme
9%
Posttranslational Modification
9%
Protein Glycosylation
8%
Surface-Enhanced Laser Desorption/Ionization
8%
Gleason Score
7%
Phosphoproteomics
7%
Quantitative Proteomics
7%
Creatine Kinase
7%
Protein Characterization
7%
Monoclonal Antibody
7%
CA-125
7%
Clinical Biochemistry
7%
CA19-9
6%
Glycopeptide
6%
Colon
6%
Troponin T
6%
Transcriptomics
6%
Isoform
6%
Liquid Chromatography-Mass Spectrometry
6%
Tandem Mass Spectrometry
6%
Time-of-Flight Mass Spectrometry
5%
Serum Total Protein
5%
Serum (Blood)
5%
Plasma Protein
5%
Chromosome Instability
5%
Phosphoprotein
5%
Epigenetics
5%
Matrix-Assisted Laser Desorption-Ionization
5%
Metalloprotease Inhibitor
5%
Magnetism
5%
Keyphrases
Prostate-specific Antigen
56%
Prostate Cancer
51%
Total Prostate-specific Antigen
45%
Prostate-specific Antigen Level
22%
Proteogenomics
22%
Proteomics
19%
Aggressive Prostate Cancer
16%
Total PSA
16%
Proteomic Analysis
14%
Free PSA
14%
Early Detection
13%
Prostate Health Index
13%
Clear Cell Renal Cell Carcinoma (ccRCC)
12%
Creatine kinase-MB (CK-MB)
12%
Radical Prostatectomy
12%
Tumor
11%
Serum Markers
11%
Multicentre Evaluation
10%
Prostate Cancer Screening
10%
Benign Prostatic Hyperplasia
9%
Cardiac Troponin
9%
Confidence Interval
9%
Gleason Score
9%
PSA Testing
8%
Clinical Utility
8%
Glycoprotein
8%
National Cancer Institute
8%
Pancreatic Ductal Adenocarcinoma
8%
Emergency Patients
8%
Amsterdam Principles
8%
Data Quality Metrics
8%
Thrombomodulin
8%
Elecsys
8%
Immunoassay
8%
Clinically Significant Prostate Cancer
8%
Preeclampsia
7%
Mass Spectrometry Data
7%
Serum Samples
7%
Carbohydrate Antigen 125 (CA125)
7%
Breast Cancer
7%
Glycoproteomics
6%
Localized Prostate Cancer
6%
Occupancy
6%
Tumor Tissue
6%
Clinical Proteomic Tumor Analysis Consortium
6%
Post-translational Modification
6%
Prostate Biopsy
6%
Proteomics Data
6%
Clinical Proteomics
6%
Prostatic Cancer
6%
Medicine and Dentistry
Prostate Cancer
90%
Prostate Specific Antigen
86%
Malignant Neoplasm
34%
Proteomics
31%
Neoplasm
25%
Biological Marker
24%
Disease
18%
Biopsy
18%
Ovarian Cancer
16%
Prostatectomy
16%
Breast Cancer
15%
Cancer Diagnosis
14%
Tumor Marker
13%
Tumor Antigen
12%
Proteogenomics
10%
Immunoassay
10%
CA-125
9%
Cancer
8%
Gleason Score
8%
Cardiac Troponin
8%
Prostate Biopsy
8%
Clear Cell Renal Cell Carcinoma
8%
Clinical Trial
7%
Diagnosis
7%
Prostate Disease
7%
Prostate Hypertrophy
7%
Hepatocellular Carcinoma
7%
Colon Cancer
7%
Adnexal Mass
6%
Urinary System
6%
Thrombomodulin
6%
Troponin I
6%
Troponin T
6%
Colorectal Cancer
6%
Creatine Kinase MB
6%
Recurrent Disease
5%
Immunoradiometric Assay
5%
Pre-Eclampsia
5%
Digital Rectal Examination
5%
Clinical Assessment
5%
Risk Stratification
5%
Metastatic Carcinoma
5%
